Notice of AGM is Enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences has called its 19th AGM on September 30, 2025, at 11:30 AM via video conferencing. Shareholders will consider adopting the audited standalone and consolidated financial statements for FY ended March 31, 2025, and re-appoint Mr. Rajesh Gupta as Managing Director, who retires by rotation. The notice also seeks approval to ratify the Cost Auditor's remuneration of Rs. 80,000 per annum for FY 2025-26 for M/s Shreya Sahu & Associates. Two special resolutions seek shareholders' approval to reduce the remuneration of Mr. Rajesh Gupta (MD) to a maximum CTC of Rs. 1,00,000 per month and Mrs. Saruchi Gupta (Whole-time Director) to a maximum CTC of Rs. 50,000 per month, effective October 1, 2025. Additionally, the company proposes appointing M/s Anil Negi & Company as Secretarial Auditors for five consecutive years (FY 2025-26 to FY 2029-30) at Rs. 80,000 per year plus taxes. The explanatory statement reveals the company suffered losses due to a steep rise in material costs, supply chain issues, and delays in payments from State Medical Corporations, prompting cost-control measures including the director pay cuts.
The director remuneration cuts indicate management is sharing financial pain with shareholders during a loss-making period, which may be viewed positively by retail investors as a sign of cost discipline. However, the admitted losses and debtor collection issues from state medical corporations point to ongoing financial stress, which could weigh on sentiment. The AGM items are largely procedural, but the underlying disclosure of business difficulties is a negative signal worth monitoring.